Healthcare [ 4/11 ] | Biotechnology [ 53/112 ]
US | NASDAQ | Stock
| Reported Date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| May 8, 23 | -0.58 Increased by +62.82% | 1.82 Decreased by -72.46% |
| Mar 29, 23 | -0.76 Increased by +98.09% | -0.42 Decreased by -192.74% |
| Nov 14, 22 | -2.12 | -0.89 Decreased by -155.28% |
| Aug 15, 22 | -0.88 | -1.07 Increased by +16.60% |
| May 12, 22 | -1.56 | -0.95 Decreased by -67.59% |
| Mar 24, 22 | -39.85 | -2.46 Decreased by -617.85% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Mar 31, 23 | 17.91 M Increased by +N/A% | -27.34 M Increased by +15.44% | Decreased by -152.66% Decreased by N/A% |
| Dec 31, 22 | 0.00 Decreased by N/A% | -37.41 M Increased by +42.41% | Decreased by N/A% Decreased by N/A% |
| Sep 30, 22 | 0.00 Decreased by N/A% | -91.87 M Decreased by -910.37% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 22 | 0.00 - | -31.57 M - | Decreased by N/A% - |
| Mar 31, 22 | 0.00 - | -32.34 M - | Decreased by N/A% - |
| Dec 31, 21 | 0.00 - | -64.97 M - | Decreased by N/A% - |
| Dec 31, 20 | 0.00 - | -9.09 M - | Decreased by N/A% - |
Arcellx, Inc., a clinical-stage biotechnology company, engages in the development of various immunotherapies for patients with cancer and other incurable diseases. The company's lead ddCAR product candidate is CART-ddBCMA, which is in phase 1 clinical trial for the treatment of patients with relapsed or refractory (r/r) multiple myeloma (MM). It is also developing ACLX-001, an immunotherapeutic combination composed of ARC-T cells and bi-valent SparX proteins targeting BCMA to treat r/r MM; ACLX-002 and ACLX-003 for treating r/r acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS); and other AML/MDS product candidates, as well as solid tumor programs. The company was formerly known as Encarta Therapeutics, Inc. and changed its name to Arcellx, Inc. in January 2016. Arcellx, Inc. was incorporated in 2014 and is headquartered in Gaithersburg, Maryland.